Parmax Pharma quarterly results and financials

Parmax Pharma (BSE 540359)₹133.70−1.00%(2 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Parmax Pharma reported sales of ₹3.30 Cr, down 31.5% from Mar 2025, and net profit of −₹0.57 Cr. For the year to Mar 2026, sales were ₹12.10 Cr and net profit −₹4.15 Cr.

Sales (Mar 2026): ₹3.30 Cr
Net profit (Mar 2026): −₹0.57 Cr
Sales (FY Mar 2026): ₹12.10 Cr
Net profit (FY Mar 2026): −₹4.15 Cr
EPS (Mar 2026): ₹−1.56
Borrowings (Mar 2026): ₹11.54 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Parmax Pharma quarterly results

₹ crore unless stated; each column is a quarter.

Parmax Pharma Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	1.39	4.06	1.32	4.25	7.81	9.27	6.27	4.82	1.95	2.52	4.32	3.30
Expenses	2.04	4.83	2.47	5.05	7.30	9.06	6.16	5.38	2.18	4.11	4.52	4.85
Operating Profit	−0.66	−0.78	−1.16	−0.81	0.52	0.21	0.12	−0.57	−0.26	−1.60	−0.21	−1.56
OPM %	−46.4%	−18.9%	−86.4%	−18.7%	6.6%	2.2%	1.8%	−11.6%	−12.8%	−62.8%	−4.6%	−46.8%
Other Income	0.02	0.02	0.02	0.02	0.02	0.13	0.02	−1.18	0.02	0.02	0.02	0.04
Interest	0.11	0.19	0.17	0.17	0.12	0.12	0.12	0.25	0.29	0.23	0.29	0.51
Depreciation	0.43	0.44	0.46	0.42	0.41	0.41	0.42	−0.19	0.25	0.27	0.28	0.26
Profit before tax	−1.17	−1.36	−1.74	−1.35	0.00	−0.20	−0.39	−1.78	−0.75	−2.07	−0.73	−2.26
Tax %	0.0%	0.0%	0.0%	6.6%	0.0%	0.0%	0.0%	−16.8%	0.0%	0.0%	0.0%	−74.5%
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	−1.06	0.00	0.00	0.00	0.00
Net Profit	−1.17	−1.36	−1.74	−1.44	0.00	−0.21	−0.38	−1.48	−0.75	−2.07	−0.72	−0.57
EPS (Rs)	−3.16	−3.67	−4.70	−3.90	0.04	−0.60	−1.05	−4.00	−2.04	−5.58	−1.96	−1.56

Parmax Pharma profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Parmax Pharma Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	0.00	0.00	11.88	11.98	20.91	26.16	18.22	15.37	11.01	28.17	12.10	12.09
Expenses	0.04	0.04	10.79	10.86	19.12	22.67	15.64	13.12	14.35	27.89	15.72	15.66
Operating Profit	−0.06	−0.06	1.09	1.12	1.78	3.44	2.58	2.26	−3.38	0.27	−3.65	−3.63
OPM %	—	—	9.2%	9.3%	8.5%	13.2%	14.2%	14.7%	−30.5%	0.9%	−30.0%	−30.0%
Other Income	0.07	0.07	0.06	0.06	0.11	0.10	0.07	0.05	0.06	−1.04	0.06	0.10
Interest	0.00	0.00	0.05	0.04	0.14	0.38	0.40	0.36	0.63	0.60	1.25	1.32
Depreciation	0.00	0.00	1.10	1.04	1.02	1.95	1.94	1.89	1.72	1.04	1.02	1.06
Profit before tax	0.00	0.00	0.00	0.09	0.72	1.20	0.30	0.03	−5.63	−2.38	−5.82	−5.81
Tax %	200.0%	100.0%	—	20.0%	41.0%	38.0%	54.8%	375.0%	1.8%	−12.6%	−29.0%	—
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	−0.99	0.00	0.00
Net Profit	0.00	0.00	0.00	0.07	0.42	0.74	0.13	−0.09	−5.74	−2.08	−4.15	−4.11
EPS (Rs)	0.00	−0.04	0.00	0.22	1.16	2.01	0.38	−0.28	−15.44	−5.61	−11.16	−11.14
Dividend payout %	—	0.0%	—	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Parmax Pharma balance sheet

₹ crore, at each year end.

Parmax Pharma Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	4.04	4.46	4.46	4.46	4.46	4.46	4.46	4.46	4.46	4.44	4.45	4.46
Reserves	0.13	0.12	0.11	0.12	0.19	0.62	1.38	1.52	1.41	−4.36	−6.44	−10.61
Borrowings	0.80	0.47	1.03	1.97	5.53	5.27	5.90	5.19	5.39	5.92	7.72	11.54
Other Liabilities	0.03	0.05	2.14	10.14	9.59	10.79	11.07	6.86	6.42	9.36	13.09	22.77
Total Liabilities	5.00	5.10	7.74	16.69	19.77	21.14	22.81	18.03	17.68	15.36	18.82	28.16
Fixed Assets	2.54	2.54	2.73	5.88	4.94	9.68	10.87	10.47	9.53	9.29	7.99	7.88
CWIP	0.00	0.00	0.00	0.00	3.32	0.00	0.00	0.00	0.00	0.09	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.21	0.19	0.21	0.00	0.00	0.00	0.41	0.41
Other Assets	2.46	2.56	5.01	10.81	11.30	11.27	11.73	7.56	8.15	5.98	10.42	19.87
Inventories	0.00	0.00	1.77	3.23	3.98	2.71	3.96	2.86	4.32	2.40	3.32	7.86
Trade receivables	0.09	0.10	0.13	1.98	1.16	3.31	1.66	0.69	0.63	1.83	1.29	3.17
Cash & equivalents	0.22	0.32	0.18	0.97	1.58	1.78	2.56	1.06	0.42	0.06	0.10	0.66
Total Assets	5.00	5.10	7.74	16.69	19.77	21.14	22.81	18.03	17.68	15.36	18.82	28.16

Parmax Pharma cash flow

₹ crore, for each year.

Parmax Pharma Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	−0.07	0.00	−0.51	3.89	0.93	2.83	3.54	0.76	0.34	−0.21	−0.97	−2.37
Cash from investing activity	0.00	0.00	−0.18	−4.22	−3.40	−2.39	−3.14	−1.52	−0.93	−1.58	−0.69	−0.89
Cash from financing activity	0.00	0.11	0.57	1.15	3.11	−0.24	0.41	−0.92	−0.05	1.44	1.41	3.82
Net cash flow	−0.05	0.08	−0.13	0.78	0.60	0.19	0.77	−1.68	−0.64	−0.35	−0.25	0.55
Capex	0.00	0.00	0.20	4.24	3.42	2.41	3.16	1.54	0.95	1.60	0.71	0.91
Free cash flow	−0.05	0.00	−0.68	−0.34	−2.48	0.41	0.37	−0.77	−0.60	−1.78	−1.65	−3.25
CFO / OP %	300.0%	0.0%	1,000.0%	359.0%	83.0%	159.0%	103.0%	29.0%	15.0%	6.0%	−369.0%	65.0%

Parmax Pharma ratios

Working-capital days and returns, by year.

Parmax Pharma Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	—	—	—	59	34	57	22	13	14	59	16	94
Inventory days	—	—	—	202	278	87	106	154	286	123	55	289
Days payable	—	—	—	608	644	311	268	299	309	382	172	529
Cash conversion cycle	—	—	—	−347	−332	−167	−140	−132	−10	−200	−102	−146
Working capital days	—	—	—	−60	−72	−56	−48	−36	0	−116	−40	−200
ROCE %	0.8%	0.2%	0.2%	0.7%	1.6%	8.5%	14.4%	6.2%	3.7%	−58.3%	−12.4%	−82.9%

Parmax Pharma: frequently asked questions

What are the latest quarterly results of Parmax Pharma?

For the Mar 2026 quarter, Parmax Pharma reported sales of ₹3.30 Cr, down 31.5% year on year and net profit of −₹0.57 Cr. The operating margin was −46.8%.

What is the annual revenue of Parmax Pharma?

Parmax Pharma's sales for the year to Mar 2026 were ₹12.10 Cr; over the last twelve months they were ₹12.09 Cr.

What is the net profit of Parmax Pharma?

Net profit for the year to Mar 2026 was −₹4.15 Cr, and −₹4.11 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−11.14.

How much debt does Parmax Pharma have?

Parmax Pharma reported borrowings of ₹11.54 Cr at Mar 2026, against cash and equivalents of ₹0.66 Cr.

What is the free cash flow of Parmax Pharma?

Cash from operations was −₹2.37 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹3.25 Cr.

Loading…